Afluria Quadrivalent Influenza Vaccine

Product Description:
Afluria Quadrivalent is an inactivated influenza vaccine designed to protect against four different flu viruses; two influenza A viruses and two influenza B viruses. As a quadrivalent vaccine, Afluria is formulated to provide a broader protection against the circulating flu strains. It is manufactured using egg-based technology and is approved for use in individuals aged 5 years and older.
Technician Specifications:

• Formulation: Inactivated quadrivalent influenza vaccine
• Strain Composition: Updated annually to match WHO recommendations
• Administration: Intramuscular injection
• Dosage: 0.5 mL per dose
• Preservative: Thimerosal-free (prefilled syringe), contains thimerosal (multi-dose vial)
• Storage: Refrigerated at 2°C to 8°C (35°F to 46°F)
• Shelf Life: Check expiration date on packaging; do not use expired vaccines
• Packaging: Available in prefilled syringes and multi-dose vials

Common Applications/User Groups:

• General Population aged 5 years and older
• Healthcare Workers
• Elderly Individuals
• Individuals with Chronic Health Conditions
• Pregnant Women
• Travelers
• Educational Institutions

Overview of Seqirus:
Seqirus is a global leader in the prevention of influenza, standing as one of the largest influenza vaccine companies in the world. With a heritage of innovation and cutting-edge technology, Seqirus is at the forefront of vaccine development and production. Their commitment to public health and safety is demonstrated through their extensive portfolio of influenza vaccines and their rapid response to pandemic threats. Seqirus operates state-of-the-art production facilities and uses both egg-based and cell-based technologies to produce influenza vaccines. Their authority in the influenza vaccine space is reinforced by their collaboration with global health organizations and their continuous effort to enhance vaccine efficacy and accessibility.